Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

BACKGROUND: Recently it has been recognized that stromal markers could be used as a clinically relevant biomarker for therapy response and prognosis. Here, we report on a serum marker for stromal activation, A Disintegrin and Metalloprotease 12 (ADAM12) in colorectal cancer (CRC). METHODS: Using gen...

Descripción completa

Detalles Bibliográficos
Autores principales: ten Hoorn, Sanne, Waasdorp, Cynthia, van Oijen, Martijn G. H., Damhofer, Helene, Trinh, Anne, Zhao, Lan, Smits, Lisanne J. H., Bootsma, Sanne, van Pelt, Gabi W., Mesker, Wilma E., Mol, Linda, Goey, Kaitlyn K. H., Koopman, Miriam, Medema, Jan Paul, Tuynman, Jurriaan B., Zlobec, Inti, Punt, Cornelis J. A., Vermeulen, Louis, Bijlsma, Maarten F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004139/
https://www.ncbi.nlm.nih.gov/pubmed/35413826
http://dx.doi.org/10.1186/s12885-022-09436-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004139/
https://www.ncbi.nlm.nih.gov/pubmed/35413826
http://dx.doi.org/10.1186/s12885-022-09436-0

Ejemplares similares